Repare Therapeutics (RPTX) Competitors $1.43 +0.02 (+1.42%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.42 -0.01 (-0.42%) As of 05/2/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RPTX vs. DSGN, CDTX, ENGN, RZLT, DRUG, HUMA, PLX, KOD, SLRN, and AARDShould you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Design Therapeutics (DSGN), Cidara Therapeutics (CDTX), enGene (ENGN), Rezolute (RZLT), Bright Minds Biosciences (DRUG), Humacyte (HUMA), Protalix BioTherapeutics (PLX), Kodiak Sciences (KOD), Acelyrin (SLRN), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. Repare Therapeutics vs. Design Therapeutics Cidara Therapeutics enGene Rezolute Bright Minds Biosciences Humacyte Protalix BioTherapeutics Kodiak Sciences Acelyrin Aardvark Therapeutics Design Therapeutics (NASDAQ:DSGN) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings. Does the MarketBeat Community prefer DSGN or RPTX? Repare Therapeutics received 33 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 64.18% of users gave Repare Therapeutics an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformDesign TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Repare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% Do institutionals and insiders believe in DSGN or RPTX? 56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by insiders. Comparatively, 21.6% of Repare Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to DSGN or RPTX? In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Repare Therapeutics' average media sentiment score of 0.28 beat Design Therapeutics' score of 0.00 indicating that Repare Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repare Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, DSGN or RPTX? Design Therapeutics has higher earnings, but lower revenue than Repare Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$66.86M-$0.88-5.28Repare Therapeutics$53.48M1.14-$93.80M-$2.00-0.72 Do analysts rate DSGN or RPTX? Design Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 72.04%. Repare Therapeutics has a consensus price target of $4.50, indicating a potential upside of 214.69%. Given Repare Therapeutics' higher probable upside, analysts clearly believe Repare Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is DSGN or RPTX more profitable? Design Therapeutics has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. Design Therapeutics' return on equity of -18.01% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -18.01% -17.38% Repare Therapeutics -99.76%-40.87%-35.07% Which has more risk and volatility, DSGN or RPTX? Design Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. SummaryRepare Therapeutics beats Design Therapeutics on 8 of the 15 factors compared between the two stocks. Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPTX vs. The Competition Export to ExcelMetricRepare TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.79M$6.85B$5.55B$8.02BDividend YieldN/A2.97%5.09%4.23%P/E Ratio-0.727.4422.6918.83Price / Sales1.14257.59404.29106.72Price / CashN/A65.8538.1834.62Price / Book0.286.576.794.33Net Income-$93.80M$143.14M$3.22B$247.97M7 Day Performance14.40%3.35%3.34%3.16%1 Month Performance36.19%10.29%6.89%8.10%1 Year Performance-58.55%-3.45%16.09%4.99% Repare Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPTXRepare Therapeutics3.3689 of 5 stars$1.43+1.4%$4.50+214.7%-57.3%$60.79M$53.48M-0.72180Upcoming EarningsNews CoverageDSGNDesign Therapeutics1.2266 of 5 stars$4.06+4.6%$8.00+97.0%+27.4%$230.46MN/A-4.7840Upcoming EarningsCDTXCidara Therapeutics4.2631 of 5 stars$21.03-2.4%$39.14+86.1%+71.1%$230.34M$1.28M-0.8290Analyst ForecastNews CoveragePositive NewsHigh Trading VolumeENGNenGene3.4198 of 5 stars$3.99+2.6%$23.29+483.6%-75.1%$229.40MN/A-6.8831Analyst ForecastShort Interest ↑RZLTRezolute2.7415 of 5 stars$3.76-2.3%$26.43+602.9%+34.7%$227.61MN/A-3.0840Short Interest ↑DRUGBright Minds Biosciences3.3649 of 5 stars$32.18-1.6%$84.33+162.1%+2,975.8%$226.68MN/A-189.28N/ANews CoveragePositive NewsGap UpHUMAHumacyte2.8435 of 5 stars$1.46+1.4%$13.71+839.3%-70.2%$226.47M$1.57M-1.09150Upcoming EarningsPLXProtalix BioTherapeutics2.8283 of 5 stars$2.85flat$15.00+426.3%+158.6%$222.39M$53.40M-21.92200Analyst RevisionNews CoveragePositive NewsKODKodiak Sciences4.0362 of 5 stars$4.21+2.4%$9.00+113.8%+29.7%$222.07MN/A-1.1590News CoveragePositive NewsSLRNAcelyrin2.9788 of 5 stars$2.18+0.5%$9.60+340.4%-39.5%$219.98MN/A-0.89135News CoveragePositive NewsAARDAardvark TherapeuticsN/A$10.12+27.6%$31.50+211.3%N/A$219.56MN/A0.0018 Related Companies and Tools Related Companies Design Therapeutics Alternatives Cidara Therapeutics Alternatives enGene Alternatives Rezolute Alternatives Bright Minds Biosciences Alternatives Humacyte Alternatives Protalix BioTherapeutics Alternatives Kodiak Sciences Alternatives Acelyrin Alternatives Aardvark Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPTX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RPTX Stock Free RPTX Stock Alerts